Enhertu

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Enhertu
May 27, 2025, 17:55 | Opinion
Amol Akhade: DESTINY-Breast09 is One of ASCO 2025’s Most Anticipated Trials
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on LinkedIn:…
May 13, 2025, 10:59 | Science
Naoto T Ueno: The Impact of Enhertu on Quality of Life
Naoto T Ueno, Director of the University of Hawaii Cancer Center, shared an article on X:…
May 8, 2025, 13:38 | Blog
Komal Jhaveri: First Phase III Trial to Demonstrate Benefit of Enhertu in Early Breast Cancer
Komal Jhaveri, Patricia and James Cayne Chair for Junior Faculty, posted on LinkedIn: "Hot off…
Apr 22, 2025, 11:10 | Oncolibrary
DESTINY-Breast09 trial: Enhertu + Pertuzumab Improves PFS in First-Line HER2+ Metastatic Breast Cancer
AstraZeneca and Daiichi Sankyo have announced that the combination of Enhertu (trastuzumab deruxtecan) and pertuzumab…
Apr 11, 2025, 02:26 | Drugs
Enhertu (Trastuzumab deruxtecan): What patients need to know?
Cancer treatment has advanced significantly, and one of the most promising breakthroughs is Trastuzumab deruxtecan.…
Apr 10, 2025, 14:00 | Drugs
Trastuzumab deruxtecan (Enhertu): Uses in Cancer, Side Effects, Dosage, Expectations, and More
Trastuzumab deruxtecan (Enhertu) is a smart drug that targets HER2-positive cancer cells, delivering a potent…
Mar 6, 2025, 12:41 | Oncolibrary
Daiichi Sankyo's and Astrazeneca's press release on ENHERTU®: Latest Updates from DESTINY-Gastric04 trial
Daiichi Sankyo and Astrazeneca issued a press release on March 6, 2025, about the latest…
Mar 4, 2025, 11:18 | Blog
Elvina Almuradova: ENHERTU Brings New Hope for Gastric Cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a…
Feb 9, 2025, 16:06 | Blog
Janice Cowden: Dosing and side effects with Trodelvy, Enhertu, Kadcyla and ADCs in clinical trial
Janice Cowden, Former nurse, Cancer patient and Advocate, posted on LinkedIn: "Help the Patient-Centered Dosing…
Nov 2, 2024, 05:07 | Blog
Razelle Kurzrock: Expanding HER2 horizons - Implications for NSCLC and beyond
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…
Oct 23, 2024, 14:45 | Blog
Paolo Tarantino: How do we build a new generation of safer and more active ADCs for treating cancer
Paolo Tarantino and Raffaele Colombo shared posts on X, about recent paper published in Cancer…
Oct 1, 2024, 18:11 | Blog
Julia Maués: The Spanish government will now cover Enhertu and Trodelvy
Julia Maués, Co-Founder of GRASP, shared a post on X by Spain's Ministry of Health,…
Sep 19, 2024, 16:25 | Insight
Razelle Kurzrock: What’s old is new again
Razelle Kurzrock shared a post on X: "What’s old is new again!! Her2 expression across cancers…
Aug 4, 2024, 23:45 | Stories
Abigail Johnston: To say that my anxiety is flaring is a bit of an understatement
Abigail Johnston,Director of Mentorship at Project LIFE MBC, shared on X: "Scanxiety... Tomorrow is my…
Jun 12, 2024, 02:06 | Drugs
FDA Greenlights Enhertu for Advanced HER2-Positive Tumors - The Babak Lab
Maria Babak shared a post by The Babak Lab, adding:           …
Jun 10, 2024, 16:23 | Blog
Laura Bobolts: Here are my top 3 studies from ASCO2024
Laura Bobolts, Senior Vice President, Clinical Strategy and Growth at OncoHealth, posted on LinkedIn: "ASCO2024 is…
Jun 7, 2024, 08:54 | Insight
Andrew Allen: What an exciting time to be in the field of personalized cancer vaccines
Andrew Allen, President, CEO and Co-Founder at Gritstone Bio, recently shared on LinkedIn: "Cancer immunotherapy…
Jun 5, 2024, 05:51 | Blog
Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24
Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill…
May 4, 2024, 10:27 | Insight
Paolo Tarantino: HER2 is about to change again
Paolo Tarantino shared a previous post of him on X and added: "HER2 is about…
Apr 29, 2024, 20:00 | Opinion
Erika Hamilton: Really feel like we don't need to be testing for HER-2 for TDXd in breast cancer
Erika Hamilton shared a post by Giuseppe Curigliano, Chief of the Clinical Division of Early…
Apr 12, 2024, 05:16 | Drugs
Tanja Obradovic: Era of antibody drug conjugates just got even more exciting with the first tumor-agnostic approval for ADC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: "Era…
Sep 17, 2023, 18:10 | Insight
Danielle Backers: ...even when it gets overwhelming, it's a fulfilling journey and a much better one with friends in the oncology space to discuss various topics with.
Quoting Danielle Backers on LinkedIn: ''The oncology pharmacy landscape is ever-changing with new drug approvals, accelerated…
All: 22 Posts: 1 - 100
Special Coverage